Ipamorelin and CJC-1295 work through different receptors than sermorelin. Combining them with sermorelin stimulates GH release through two separate pathways simultaneously, producing larger GH pulses than any single peptide alone.
Sermorelin monotherapy is the appropriate starting point for most adults with age-related GH decline. Combination protocols are reserved for patients whose IGF-1 does not reach the therapeutic range on monotherapy after 90 days, or for patients with specific performance or recovery goals that require a stronger GH stimulus than sermorelin alone can produce. This guide explains the mechanism, clinical rationale, and practical differences between the most common peptide stacks.
- Any provider that states lab testing is not required is prescribing without confirmed clinical indication
- Ask for the pharmacy name and its 503A or 503B registration number
- USP 797 (sterility) and USP 85 (endotoxicity) are the specific standards to ask about
- Compare the all-in monthly cost, not the headline price
- A Certificate of Analysis (COA) for your specific batch should be available on request
How Sermorelin, Ipamorelin, and CJC-1295 Work Differently
Sermorelin, ipamorelin, and CJC-1295 each stimulate GH release through distinct mechanisms. Sermorelin binds to GHRH receptors in the anterior pituitary. Ipamorelin is a GHRP (growth hormone-releasing peptide). It binds to the ghrelin receptor (GHS-R1a) in the pituitary, triggering GH release through a separate pathway. CJC-1295 is a long-acting GHRH analog with a half-life of 6 to 8 days, compared to sermorelin's half-life of minutes.
| Peptide | Class | Half-life | Primary effect |
|---|---|---|---|
| Sermorelin | GHRH analog | Minutes | Stimulates pituitary via GHRH receptor |
| Ipamorelin | GHRP | About 2 hours | Stimulates pituitary via ghrelin receptor |
| CJC-1295 | GHRH analog (long-acting) | 6 to 8 days | Sustained baseline GH stimulation |
| Sermorelin + ipamorelin | Dual-pathway stack | Combined | Larger GH pulses via two simultaneous pathways |
When Stacking Is Clinically Justified
- Monotherapy non-response after 90 days of correct dosing: first indication to consider adding ipamorelin
- Active injury recovery, particularly tendons, ligaments, or cartilage
- Very low baseline IGF-1 (below the lower limit of the reference range)
- Established performance goals beyond baseline GH restoration
Sermorelin and Ipamorelin: The Most Common Stack
Ipamorelin is the preferred GHRP to stack with sermorelin for two reasons. First, it does not raise cortisol or prolactin at standard doses, which distinguishes it from older GHRPs like GHRP-2 and GHRP-6 that have meaningful cortisol side effects. Second, its 2-hour half-life aligns well with the bedtime dosing window, allowing it to work alongside the sermorelin pulse during the initial slow-wave sleep cycle.
The typical stack is 100 to 200 mcg sermorelin plus 100 to 200 mcg ipamorelin, administered together subcutaneously at bedtime. Because the two peptides work through different receptors, they do not compete for the same binding site and their effects are additive. The result is a larger GH pulse than either produces alone.
CJC-1295: Less Frequent Dosing, Sustained Stimulation
CJC-1295 extends the GH-stimulating effect of a GHRH signal for 6 to 8 days per injection. It is used in protocols where daily injections are impractical or where the patient wants sustained baseline GH elevation rather than acute nightly pulses. CJC-1295 is most commonly combined with ipamorelin. The tradeoff is reduced pulse-alignment benefit: CJC-1295 elevates baseline GH more continuously and does not replicate the natural bedtime GH pulse pattern that sermorelin targets.
BPC-157: Tissue Repair, Not GH Axis Stimulation
BPC-157 is occasionally prescribed alongside sermorelin but does not work through the GH axis. It is a synthetic peptide used for its local tissue repair effects: tendon and ligament healing, gut lining integrity, and anti-inflammatory properties. For patients with injury recovery goals alongside GH axis restoration, BPC-157 addresses a different mechanism. It is not a substitute for sermorelin.
Why to Start with Monotherapy
Starting a combination protocol before establishing a monotherapy baseline makes it impossible to know which peptide is producing which effect. If side effects appear, the cause is unclear. If IGF-1 rises more than expected, the individual contribution of each peptide is unknown. A 90-day sermorelin monotherapy trial establishes the baseline response and gives the physician the data to make an informed decision about whether to add a second peptide.
Bottom Line
Sermorelin monotherapy is the right starting point. Ipamorelin is the appropriate first addition for patients who do not achieve an adequate IGF-1 response at 90 days or who have recovery goals beyond baseline GH restoration. CJC-1295 suits patients who want sustained GH elevation with less frequent injections. Stacking decisions should always be made by a physician based on 90-day lab data, not initiated at the start of treatment.
Frequently Asked Questions
Should I start sermorelin alone or with ipamorelin from the beginning?
Starting with sermorelin monotherapy is the correct clinical approach. Beginning a combination protocol before establishing a monotherapy baseline makes it impossible to know which peptide is driving which effect or causing which side effect. A 90-day sermorelin-only trial establishes the individual pituitary response. Providers that recommend starting with a stack at initiation are optimizing revenue, not clinical outcomes.
What is the clinical difference between ipamorelin and CJC-1295?
Ipamorelin is a GHRP that works through the ghrelin receptor (GHS-R1a), producing a GH pulse with minimal effect on cortisol or prolactin. Its half-life is approximately 2 hours. CJC-1295 is a long-acting GHRH analog with a half-life of 6 to 8 days; it produces sustained, low-level GH elevation rather than pulsatile release. Ipamorelin is the preferred first addition to sermorelin because it amplifies pulsatile GH release through a different receptor without the hormonal side effects of older GHRPs.
Can sermorelin be stacked with BPC-157?
BPC-157 is sometimes prescribed alongside sermorelin but operates through a completely separate mechanism. BPC-157 is a synthetic peptide used for local tissue repair effects: tendon and ligament healing, gut lining integrity, and anti-inflammatory action. It does not work through the GH axis. If the clinical goal is GH axis restoration, BPC-157 does not contribute to that outcome. If the patient also has a tissue injury or recovery goal, BPC-157 addresses that separately.
Does combining sermorelin with ipamorelin increase side effects?
At standard doses, adding ipamorelin to a sermorelin protocol does not substantially increase the side effect burden. Ipamorelin is specifically selected over other GHRPs because it does not elevate cortisol or prolactin. At the doses used in standard telehealth protocols (100 to 200 mcg of each), the risk of GH oversaturation is low. Starting monotherapy first and adding ipamorelin only when indicated keeps the risk profile predictable.
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Frontiers in Pharmacology, 2021. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.627533/full
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMID: 18046908. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
